RxSight business development chief sells $14,205 in stock

Eric Weinberg, Chief Business Development Officer of RxSight, Inc., sold 2,041 shares of company stock for a total of $14,205 on September 2, 2026, at $6.96 per share. The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units, not as a discretionary trade. The stock currently trades at $7.03, down 32.5% year-to-date, though InvestingPro analysis suggests the shares are undervalued. Weinberg acquired 5,370 shares on August 31, 2026, from RSU vesting at $0 per share, with additional vesting scheduled through February 2029. He now directly holds 200,348 shares and indirectly holds 299,978 shares via a trust. RxSight recently beat Q2 2026 earnings expectations but withdrew its full-year guidance, leading Stifel to cut its price target to $7.00.